Novavax
| Company type | Public company |
|---|---|
| |
| ISIN | US6700024010 |
| Industry | Biotechnology |
| Founded | 1987 |
| Headquarters | , U.S. |
Area served | Worldwide |
Key people | |
| Products | Vaccines |
| Revenue | US$1.982 billion (2022) |
Number of employees | 1,541 (2022) |
| Website | www |
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.
The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.